Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of IRO2201A 120 mg Vial in Healthy Japanese Adult Males
jRCT2031250294Phase 1Active, not recruiting
- Sponsor
- DNAVEC
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of IRO2201A and denosumab (2 arms), sponsored by DNAVEC. Primary endpoints: AUC0-t and Cmax. Started Aug 2025; status: active, not recruiting.
02
Drugs
IRO2201Adenosumab
Beyond the preview
Go deeper on jRCT2031250294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250294.